Merck & Co. shifts its cancer drug development playbook, opting for targeted collaborations with Guardant Health and Eikon Therapeutics after walking away from a major acquisition. Analysts debate whether the stock's current price fully reflects its long-term pipeline potential.
Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.
BeOne Medicines extends its collaboration with quantitative systems pharmacology firm InSysBio, aiming to optimize clinical trial dosing and mitigate cytokine release syndrome risks across its broad portfolio of 15 novel oncology assets.
Exelixis has filed its next-generation therapy zanzalintinib with U.S. regulators for metastatic colorectal cancer, marking a significant step in its clinical development and potentially enhancing its competitive position in the targeted oncology space.
Pzena Investment Management's Focused Value Strategy lagged behind its benchmark in Q4 2025, with semiconductor firm Skyworks Solutions cited as a key detractor. The fund's commentary highlights the challenges for value investing in a market dominated by AI and mega-cap stocks.
MicroStrategy, led by Michael Saylor, has added another 855 Bitcoin to its corporate treasury, a $75.3 million acquisition that solidifies its position as the world's largest public holder of the cryptocurrency despite recent market volatility.
A sharp correction in Bitcoin prices has left corporate giant MicroStrategy nursing over $1 billion in unrealized losses and triggered massive outflows from spot ETFs. Despite the sell-off, CEO Michael Saylor signals unwavering commitment, framing the downturn as a strategic buying opportunity.
The business intelligence firm, the world's largest corporate holder of Bitcoin, is now sitting on nearly $1 billion in paper losses after the cryptocurrency's recent slump below its average acquisition cost, raising questions about its high-stakes treasury strategy.
As Bitcoin grapples with volatility below $80,000, a packed U.S. economic calendar—featuring key jobs reports and MicroStrategy's Q4 earnings—is poised to dictate the cryptocurrency's near-term trajectory by shaping Federal Reserve policy expectations.
A sharp correction in Bitcoin prices has pushed MicroStrategy's massive holdings into significant paper losses, testing the resolve of the corporate sector's most vocal crypto advocate and raising questions about the sustainability of its accumulation strategy.
The Walt Disney Company announces plans for its first theme park in the Middle East—a full-scale resort in Abu Dhabi—alongside a key executive appointment aimed at refining long-term corporate strategy and investor relations.
Insurance broker Arthur J. Gallagher raises its quarterly dividend, rewarding shareholders even as it continues to pursue an active mergers and acquisitions pipeline, signaling confidence in its dual strategy of capital returns and growth.
Japanese investment firm Metaplanet has approved a significant capital raise to bolster its Bitcoin treasury and reduce debt, marking a decisive shift toward a digital asset-focused corporate strategy while expanding its operational footprint in the United States.
Despite a major new Bitcoin purchase, MicroStrategy's stock has plunged to its lowest level since September 2024, as market turbulence and mixed analyst sentiment pressure the crypto-focused software firm ahead of its earnings report.
The consumer goods giant reports resilient Q4 2025 results, beating expectations despite market headwinds, and unveils a comprehensive new strategy focused on omnichannel demand, premiumization, and AI-driven efficiency to drive growth through 2030.
The Walt Disney Company has appointed former Morgan Stanley media analyst Benjamin Swinburne to lead its investor relations and corporate strategy divisions, a move seen as strengthening its financial communications amid industry transformation.
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.
A sharp downturn in cryptocurrency markets has spilled over into the stocks of major corporate holders, with MicroStrategy and BitMine leading losses as their aggressive accumulation strategies face mounting pressure.
MicroStrategy has added nearly 3,000 Bitcoins to its corporate treasury, solidifying its lead as the largest public holder of the cryptocurrency. The purchase, funded by new stock sales, intensifies the debate over the company's valuation and the risks of its aggressive Bitcoin accumulation strategy.
Apis Capital's flagship fund, which surged 55% in 2025, spotlights clinical-stage biotech Celcuity in its latest investor letter, citing the company's novel platform for matching cancer patients with targeted therapies.
